# Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder

> **NCT00480571** · PHASE2 · COMPLETED · sponsor: **BioLineRx, Ltd.** · enrollment: 90 (estimated)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder

## Interventions

- **DRUG:** BL-1020
- **DRUG:** BL 1020 High Dose

## Key facts

- **NCT ID:** NCT00480571
- **Lead sponsor:** BioLineRx, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2009-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00480571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00480571, "Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00480571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*